EyePoint Pharmaceuticals Inc (NAS:EYPT)
$ 11.84 -0.68 (-5.43%) Market Cap: 616.68 Mil Enterprise Value: 321.95 Mil PE Ratio: 0 PB Ratio: 2.36 GF Score: 53/100

Q4 2022 EyePoint Pharmaceuticals Inc Earnings Call Transcript

Mar 02, 2023 / 01:30PM GMT
Release Date Price: $2.89 (-8.83%)
Operator

Good day, and welcome to the EyePoint Pharmaceuticals Fourth Quarter and Full Year 2022 Financial Results Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker, Mr. George Elston, Chief Financial Officer. Please go ahead.

George O. Elston
EyePoint Pharmaceuticals, Inc. - CFO

Thank you. And thank you all for joining us on today's conference call to discuss EyePoint Pharmaceuticals Fourth Quarter and Full Year 2022 Financial Results and recent corporate developments.

With me today is Nancy Lurker, Chief Executive Officer; Dr. Jay Duker, President and Chief Operating Officer; and Scott Jones, Chief Commercial Officer. Nancy will begin with a review of recent corporate updates. Dr. Duker will then discuss pipeline developments and Scott will comment on our commercial activities. I will close with commentary on the fourth quarter and full year 2022 financial results. We will then open up the call for your questions.

Earlier this

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot